SEARCH

SEARCH BY CITATION

References

  • 1
    Nicholson KG. Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect 1996;116:5163.
  • 2
    Health Protection Agency. Frequently asked questions on flu. Available from: http://www.hpa.org.uk/infections/topics_az/influenza/flufaq.htm#vacc[Accessed October 14, 2003].
  • 3
    Burls A, Clark W, Stewart T, et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess 2002;6.
  • 4
    Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003;7.
  • 5
    National Institute for Clinical Excellence. Guidance for Manufacturers and Sponsors: Technology Appraisals Process Series No. 5. London: National Institute for Clinical Excellence, 2001.
  • 6
    Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In: GoldMR, SiegelJE, RussellLB, WeinsteinMC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 7
    Felli C, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making 1998;18:95109.
  • 8
    Yokota F, Thompson K. Value of information literature analysis: a review of applications in health risk management. Med Decis Making 2004;24:28798.
  • 9
    Claxton K, Ades T. Some methodological issues in value of information analysis: an application of partial EVPI and EVSI to an economic model of Zanamivir in the treatment of Influenza. Presentation to Centre for Health Economics and Bayesian statistics, May 2002. Available from: http://www.shef.ac.uk/content/1/c6/02/96/05/Claxton.ppt[Accessed December 16, 2005].
  • 10
    Claxton K, Neuman PJ, Araki SS, Weinstein MC. The value of information: an application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care 2001;17:3855.
  • 11
    Chilcott J, Brennan A, Booth A, et al. The role of modelling in prioritising and planning clinical trials. Health Technol Assess 2003;7.
  • 12
    Burls A, Clark W, Stewart T, et al. Zanamivir for the Treatment of Influenza in Adults. London: NICE, 2000.
  • 13
    O'Brien B, Goeree R, Blackhouse G, et al. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. Value Health 2003;6:11625.
  • 14
    NICE. Technology Appraisal Guidance No. 58. Guidance on the Use of Zanamivir, Oseltamivir and Amantadine for the Treatment of Influenza. London: NICE, 2003.
  • 15
    Nicholson KG, Aoki FY, Osterhaus ADME, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000;355:184550.
  • 16
    Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283:101624.
  • 17
    MVH Group. The Measurement and Valuation of Health. First Report on the Main Survey. York: Centre for Health Economics, University of York, 1994.
  • 18
    MVH Group. The Measurement and Valuation of Health. Final report on the Modelling of Valuation Tariffs. York: Centre for Health Economics, University of York, 1995.
  • 19
    Jefferson TO, Demicheli V, Deeks JJ, Rivetti D. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Sys Rev 2000;2.
  • 20
    Murray CJ, Lopez AD, eds. The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disabilities from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press, 1996.
  • 21
    Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 2001;358:141016.
  • 22
    Fleming DM. The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun Dis Public Health 2000;3:328.
  • 23
    Office for National Statistics. Population Estimates for 1996 for England and Wales. London: Office for National Statistics, 2002.
  • 24
    Ross AM, Kai J, Salter R, Ross J, Fleming DM. Presentation with influenza-like illness in general practice: implications for use of neuramindase inhibitors. Commun Dis Public Health 2000;3:25666.
  • 25
    Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clincial complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000;19:83442.
  • 26
    Birmingham Research Unit, Royal College of General Practitioners. Annual Report of the Weekly Returns Service. Birmingham: Birmingham Research Unit, Royal College of General Practitioners, PHLS, 1999.
  • 27
    Birmingham Research Unit, Royal College of General Practitioners. Annual Report of the Weekly Returns Service. Birmingham: Birmingham Research Unit, Royal College of General Practitioners, PHLS, 2000.
  • 28
    Netten J, Curtis J. Unit Costs of Health and Social Care. Canterbury: PSSRU, University of Kent, 2001.
  • 29
    British National Formulary (39). London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2000.
  • 30
    Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester: Wiley, 2003.
  • 31
    Tappenden P, Chilcott J, Eggington S, Oakley J, McCabe C. Methods for expected value of information analysis in complex health economic models: developments on the health economics of beta-interferon and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004;8.
  • 32
    Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:77987.
  • 33
    Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modelling. Med Decis Making 2004;24:20727.